Skip to main content
logo
Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
13.56
-0.10 (-0.73%)
At close: Jun 12, 2026, 4:00 PM EDT
13.64
+0.08 (0.57%)
After-hours: Jun 12, 2026, 6:04 PM EDT

Janux Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
13.731010.598.088.613.64
Revenue Growth (YoY)
47.10%-5.55%30.99%-6.14%136.79%-
Gross Profit
13.731010.598.088.613.64
Selling, General & Admin
43.0641.7741.0526.1422.2610.33
Research & Development
127.65125.968.3954.9253.4426.24
Total Operating Expenses
170.72167.67109.4481.0675.736.57
Operating Income
-156.98-157.67-98.85-72.98-67.09-32.93
Interest Income
42.5144.0429.8514.694.030.26
Total Non-Operating Income (Expense)
42.5144.0429.8514.694.030.26
Pretax Income
-114.48-113.63-68.99-58.29-63.06-32.67
Net Income
-114.48-113.63-68.99-58.29-63.06-32.67
Net Income to Common
-114.48-113.63-68.99-58.29-63.06-32.67
Shares Outstanding (Basic)
626254444124
Shares Outstanding (Diluted)
626254444124
Shares Change (YoY)
9.24%15.28%22.12%6.14%76.24%2471.21%
EPS (Basic)
-1.84-1.83-1.28-1.32-1.52-1.39
EPS (Diluted)
-1.84-1.83-1.28-1.32-1.52-1.39
Free Cash Flow
-78.49-83.28-44.17-52.43-49.37-18.46
Free Cash Flow Per Share
-1.26-1.34-0.82-1.19-1.19-0.78
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-1143.11%-1576.67%-933.58%-902.87%-779.04%-905.39%
Profit Margin
-833.60%-1136.25%-651.62%-721.18%-732.22%-898.32%
FCF Margin
-571.57%-832.78%-417.20%-648.58%-573.24%-507.51%
EBITDA
-155-155.64-96.79-71.02-66.25-32.82
EBITDA Margin
-1128.70%-1556.38%-914.12%-878.68%-769.27%-902.28%
EBIT
-156.98-157.67-98.85-72.98-67.09-32.93
EBIT Margin
-1143.11%-1576.67%-933.58%-902.87%-779.04%-905.39%
SEC Filings: 10-K · 10-Q